S&P 500
5,987.13
+0.3%
+$16.76
DJI
42,604.72
+0.2%
+$85.08
NASDAQ
19,459.73
+0.3%
+$60.78
Bitcoin
104,696.00
-1.0%
-1,011.21
AAPL
$204.81
+0.8%
+$1.54
AMZN
$206.18
+0.2%
+$0.47
GOOG
$168.81
+0.7%
+$1.10
META
$684.38
+2.6%
+$17.54
MSFT
$464.75
+0.4%
+$1.78
NVDA
$141.23
+0.0%
+$0.01
TSLA
$331.35
-3.8%
-$12.92
Alex Dumortier, CFA
TMFAleph1
Alex Dumortier covers daily market activity from a contrarian, value-oriented perspective.
Recent Articles by Alex Dumortier, CFA

Nov 3, 2016
by Alex Dumortier, CFA
Mortgage Rates Decline As the Fed and Investors Anticipate Friday's Employment Report
Mortgage rates fell on Thursday; meanwhile, Federal Reserve policymakers and financial markets are eager for Friday morning's release of the employment situation report for October.

Jul 15, 2016
by Alex Dumortier, CFA
Herbalife Investment Reveals Bill Ackman's Psychological Limits
Distinguishing between confidence and hubris is extraordinarily difficult when you're leading a high-profile, adversarial campaign against a company, as billionaire investor Bill Ackman is discovering with his unsuccessful encounter with Herbalife Ltd.

Jul 13, 2016
by Alex Dumortier, CFA
The Sequoia Fund Finally Exits Valeant Pharmaceuticals: 2 Lessons for Investors From a Fiasco
The Sequoia Fund disclosed that it has sold its remaining stake in troubled drug company Valeant Pharmaceuticals, but there are valuable lessons for investors to learn from Sequoia's multibillion-dollar mistake.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.